DGX vs LGND: fair value comparison
Quest Diagnostics Incorporated and Ligand Pharmaceuticals Incorporated · Updated 2026-09-07
Both currently screen as overvalued on TickrTrends' Forward Fair Value model. Within Healthcare, DGX currently sits closer to the top of our discount ranking. LGND carries the stronger quality grade.
| DGX | LGND | |
|---|---|---|
| Verdict | Overvalued | Overvalued |
| Last price | $237.14 | $292.04 |
| 12-month range | $173.79–$236.22 | $179.07–$312.01 |
| Sector rank | #103 of 113 Healthcare | #108 of 113 Healthcare |
| Quality grade | C | B |
| Leverage | Moderate | Moderate |
| Margin trend | Stable | — |
| Revenue growth | Modest | — |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | — | Uptrend |
| DCF cross-check | Overvalued | — |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: DGX fair value analysis · LGND fair value analysis